Volume loss due to facial aging can be restored by facial volumization using a variety of materials. Volumization can be performed in isolation or concurrent with other facial rejuvenation procedures to obtain an optimal aesthetic result. There is a myriad of manufactured products available for volumization. The use of autologous fat as facial filler has been adopted more recently and possesses certain advantages; however, the ideal filler is still lacking. Tissue engineering may offer a solution. This technology would provide autologous soft-tissue components for use in facial volumization. The use of stem cells may enable customization of the engineered product for the specific needs of each patient.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0036-1586208 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment of the Temples: Brazilian Consensus.
Aesthetic Plast Surg
December 2024
Instituto Boggio-Medicina, ensino e pesquisa, Rua Cincinato Braga, 37, 8°Andar, Bela Vista, São Paulo, 04004-030, Brazil.
Introduction: The temporal region is emblematic and challenging due to its structural and volumetric changes during aging, which significantly affect facial aesthetics. Despite the importance of addressing temporal aging, many injectors hesitate due to the region's anatomical complexity and risk of complications. This consensus aimed to provide expert guidance on the safest and most effective treatment strategies for the temple.
View Article and Find Full Text PDFStructural Aesthetic Treatment With the Hyaluronic Acid Filler VYC-25L: Global Expert Considerations for Safe and Effective Long-Term Outcomes.
J Cosmet Dermatol
November 2024
Global Aesthetics Medical Affairs, Allergan Aesthetics, an AbbVie Company, Madrid, Spain.
Article Synopsis
- VYC-25L is a hyaluronic acid filler approved in 2019 for facial volumizing, lifting, and contouring, offering a long-lasting effect of at least 24 months.
- Experienced doctors highlight its unique properties, including high lift capacity, moldability, and tissue integration, which enhance its use in non-surgical facial aesthetics.
- Proper technique and cautious application are essential for maximizing patient benefits, including starting with the chin and jawline and following best practice principles to ensure safety and effectiveness.
Background: Cosmetically unappealing temporal volume loss can develop as a result of facial aging.
Objective: To present an evidenced-based approach towards safe and effective temple filling.
Methods: We review the underlying anatomy of the temple and optimal anatomy-driven injection techniques associated with temple volumization.
Effectiveness and Safety of a Hyaluronic Acid Filler for Chin Augmentation and Correction of Chin Retrusion: A Multi-center, Prospective, Randomized Controlled Trial.
Aesthetic Plast Surg
November 2024
Department of Plastic Surgery, Peking University Third Hospital, #49, North Garden Road, Haidian District, Beijing, People's Republic of China.
Background: The chin significantly influences facial aesthetics, contributing to the overall balance and harmony of the face. This study aimed to assess the effectiveness of the hyaluronic acid filler Hyamax® Volumizer for chin augmentation and correction of chin retrusion compared to a no-treatment control.
Methods: Participants aged 18-55 years with mild to moderate chin retrusion were randomized in a 3:1 ratio to receive either the treatment group (n = 150) or control group (n = 50).
Hyamax® Monophasic Volumizer Dermal Fillers for Chin Restoration: A Prospective, Single-Center, Investigator-Blinded, Randomized Controlled Trial.
Aesthetic Plast Surg
November 2024
Department of Plastic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan 1#, Dongcheng District, Beijing, 100730, People's Republic of China.
Background: Hyamax® Monophasic Volumizer Dermal Fillers is a newly designed hyaluronic acid soft tissue filler for chin augmentation.
Methods: A prospective, single-center, evaluator-blinded, randomized controlled study was designed to evaluate the effectiveness and safety of Hyamax® Volumizer in the correction of chin retrusion in the 18-55-year-old Chinese population for 12 months after treatment. Participants were randomized (3:1) to receive Hyamax® Volumizer injection (n = 21) or no treatment (n = 7).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!